Skip to main content
Helixmith Co., Ltd logo

Helixmith Co., Ltd — Investor Relations & Filings

Ticker · 084990 ISIN · KR7084990001 KO Manufacturing
Open in API
Filings indexed 508 across all filing types
Latest filing 2019-03-11 Remuneration Information
Country KR South Korea
Listing KO 084990

About Helixmith Co., Ltd

https://www.helixmith.com/

Helixmith is a biotechnology company specializing in the research and development of gene therapies. Established in 1996, the company focuses on creating innovative biopharmaceuticals for diseases with significant unmet medical needs. Its core activities revolve around an extensive pipeline of next-generation gene therapy products. The primary therapeutic areas of focus include neurological and cardiovascular disorders, such as peripheral artery disease and coronary artery disease. Helixmith manages a comprehensive range of capabilities, from discovery and preclinical studies to clinical development of its drug candidates.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Remuneration Information Classification · 95% confidence The document is a proxy solicitation statement (Proxy Statement) for the 23rd Annual General Meeting of ViroMed Co., Ltd. It includes details on the meeting date, agenda items (such as the approval of financial statements), and information regarding the solicitation of proxies for voting. While it contains financial statements, the primary purpose of the document is to solicit shareholder votes for the upcoming general meeting, which aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2019-03-11 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Viromed. It details the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of meeting details and agenda items for voting purposes.
2019-03-05 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal notification regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date' (a date when many companies hold their meetings). It explains the company's reasoning for holding the meeting on this date despite regulatory efforts to disperse meeting dates. This is a regulatory disclosure regarding corporate governance and meeting logistics, which does not fit into specific categories like AGM-R (presentation materials) or PSI (proxy solicitation). Therefore, it is classified as a general regulatory filing.
2019-03-05 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to specific employees/executives, including the number of shares, exercise price, and valuation methodology. In the context of Korean regulatory filings (DART), this is a specific disclosure regarding stock option grants, which falls under the category of share-related capital changes or issuance announcements. Given the options provided, 'SHA' (Share Issue/Capital Change) is the most appropriate classification as it pertains to the issuance of new shares or stock-based compensation instruments.
2019-03-05 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (Citi Korea Investor Conference 2019). It provides details such as date, location, purpose, and target audience. Since it is an announcement of an event rather than the presentation materials themselves, and it is under 5,000 characters, it falls under the category of a regulatory filing announcement regarding an event.
2019-03-05 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (Viromed) announcing a significant change (over 30%) in revenue or profit structure. This is a standard regulatory disclosure requirement in the Korean market (DART system) for listed companies to report material financial changes before the final audit is completed. It provides specific financial data points (revenue, operating profit, net income) and reasons for the change. It is not a full annual report, but a specific regulatory disclosure of financial results, fitting the 'Earnings Release' (ER) category as it provides the initial announcement of financial performance highlights.
2019-02-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.